Varsha Gandhi

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia”.

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00675-9

N/A

0.617DataRank · unranked

60 citations

Görkem Kısmalı, LaKesla R. Iles, Ganiraju C. Manyam, Mary Ayres, Lisa S. Chen +5 more

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

Blood(2025)10.1182/blood.2024027009

N/A

0.452DataRank · unranked

6 citations

Bastien Nguyen, Sai Prasad Desikan, Helen Won, Shady I. Tantawy, Samuel McNeely +22 more

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Haematologica(2021)10.3324/haematol.2021.279158

N/A

0DataRank · unranked

22 citations

Stefan Hübner, Judith A. Fox, Pietro Taverna, William G. Wierda, Steven M. Kornblau +2 more

Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors

Faculty Reviews(2021)10.12703/r/10-22

N/A

0DataRank · unranked

4 citations

Varsha Gandhi, Prithviraj Bose

Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2088

N/A

0DataRank · unranked

27 citations

Aloke Sarkar, Stefan Hübner, Zhi Tan, William G. Wierda, Abdelraouf Eldeib +4 more

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

Frontiers in Oncology(2023)10.3389/fonc.2023.1161254

N/A

0DataRank · unranked

27 citations

Mary Ayres, Natalia Baran, Janice M. Santiago‐O’Farrill, Gamze Bildik, Zhen Lü +3 more

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia

Blood Advances(2023)10.1182/bloodadvances.2023010337

N/A

0DataRank · unranked

13 citations

Gabriela Alexe, Karin Gustafsson, Elizabeth Zanetakos, Jelena Milosevic, Mary Ayres +5 more

A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics

Cancer(2023)10.1002/cncr.35077

N/A

0DataRank · unranked

5 citations

Lisa S. Chen, Joycelynne Palmer, Jianying Zhang, Timothy W. Synold, Ralf Buettner +8 more

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Blood(2023)10.1182/blood-2023-182568

N/A

0DataRank · unranked

1 citations

James D’Olimpio, Andew gillis-Smith, Seung‐Tae Lee, Nirav N. Shah, Javier Pinilla‐Ibarz +9 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia

Blood Cancer Journal(2024)10.1038/s41408-024-01142-3

N/A

0DataRank · unranked

11 citations

Priyanka Khare, Priyanka Banerjee, Cristina Ivan, Sarah Schneider, Federica Barbaglio +20 more

Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels

Blood Cancer Journal(2024)10.1038/s41408-024-01196-3

N/A

0DataRank · unranked

1 citations

Ganiraju C. Manyam, Nitin Jain, Cristina Ivan, Betty Lamothe, Mary Ayres +4 more

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

Blood Cancer Journal(2025)10.1038/s41408-025-01382-x

N/A

0DataRank · unranked

2 citations

Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Natalia Timofeeva, Neetu Singh +8 more

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0593

N/A

0DataRank · unranked

2 citations

Moises Tacam, Alex W. Tan, Mary Kathryn Pitner, LaKesla R. Iles, Xiaoding Hu +16 more

Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma

Haematologica(2020)10.3324/haematol.2019.234385

N/A

0DataRank · unranked

31 citations

Christine M. Stellrecht, Hima V. Vangapandu, Mary Ayres, Benny Abraham Kaipparettu, Jun Hyoung Park +7 more

A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2461672

N/A

0DataRank · unranked

0 citations

Prithviraj Bose, Wei Qiao, Yongying Jiang, Qi Wu, Nichole Cruz +3 more

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01076-4

N/A

0DataRank · unranked

67 citations

Le Xuan Truong Nguyen, Corey Morales, Min-Hsuan Chen, Xiwei Wu, Lisa S. Chen +7 more